Index

Tables, figures, and case studies are indicated by appending “t”, “f”, or “c” to the page number. Contents of tables are not indexed separately.

A

absorption, distribution, metabolism and excretion (ADME)
  gene therapy products, 466, 468
  preclinical testing, 302–303
accelerated assessment
  additional pathways for, 538–539
  ATMPs, 452, 453t
  CAT request for human tissues, 480
  CHMP recommendation for, 35
  conditional authorisation, 475
  EMA advice meetings, 44t
  EMA initiatives, 101
  for orphan designation products, 538
  preandemic influenza vaccines, 496
  procedures for, 475
  registration of medicinal products, 347
  regulatory mechanisms for, 3–4
  requests for, 283
See also PRIME (PRIority MEdicines)

Active Implantable Medical Device Directive (AIMDD)
  repeal of, 184–185
  transition from, 178
See also EU MDR and EU IVDR

active implantable/active medical devices
  classification change for, 146
  classification rules for, 191t
  legal framework for, 165–170
  MDR rules
    medical device legislation and classification, 191t

active pharmaceutical ingredients (API)
  EDQM inspection process, 369
  in generic products, 377

Active Substance Master File (ASMF)
  with combination products, 550
  generic medicinal products, 384
  IGDRP work on, 384
  MA dossier quality section, 280
  medicinal product registration, 350
  acute/repeat dose toxicity studies, 303

Ad Hoc Expert Group
  MAA review, 54
  meeting of, 56

adaptive and alternative pathways
  accelerated access initiatives by EMA, 295–296
  eligibility for, 295, 297f, 346
  HTA/EMA collaboration for, 88–89
  legal framework for, 296–298
  medicinal products, 296–298
  for orphan designation products, 539
  principles of, 296
  procedural guidance for, 298
  product eligibility for, 297f

Addition of Vitamins and Minerals and of Other Substances to Food Regulation, 504

Advanced Therapy Medicinal Products (ATMPs)
  authorised in EU, 455t
  borderline and criteria precluding from, 457–460
  certification of, 460
  characterisation and quality control, 462
  classification of, 456–457, 457f, 477–478
  classification procedures for, 456–460
  GTMP, 461–462, 464–465, 466
  legal framework, 480
  MA procedures for, 480
  pharmaceutical regulation evolution, 21–22
Index

preclinical development, 465–466
product characterisation, manufacturing and quality control of, 462–463
regulation, 451–470, 480
risk management for, 466–467
sCTMPs, 460–461, 462, 463–464, 465–466
subcategories of, 452–453
summary, 467–468
supply without MA grant, 455–456
TEPs, 461, 463, 465, 466

Adverse Drug Reactions (ADRs)/reporting for biosimilar medicinal products, 401
defined, 313
Eudra Vigilance databases, 318, 401
from healthcare professionals, 438
human blood or plasma products, 525
nonprescription medicinal products, 409
for paediatric product development, 100
PRAC activities for, 387
requirements of Member States, 386–387
See also pharmacovigilance

advertising and promotion, 103–114
abbreviated ads as reminders, 106
comparative advertisements, 110
contents for HCPs, 105–106
EFPIA goals and code, 104–105
enforcement by competent authorities, 120
to general public, 108
general public content, 107–108
generic medicinal products, 389
HCPs, 105–106
to healthcare professionals, 105
healthcare professionals (HCPs), 105, 106–107
Internet media, 109
jurisdictions for, 111–112
market surveillance, 110–111
medical devices, 112
nonauthorised products, 109–110
nonprescription medicinal products, 408–409
off-label information, 109–110
OTCs, 108
preapproval of material, 111–112
press releases, 108–109
regulatory framework, 103–104
regulatory strategy for, 138
sales representatives/sample distribution, 105–106
scientific service by MAA, 111
self-regulation, 104–105
affiliated countries and competent authorities, 161–163t
American Association of Tissue Banks (AATB), 473
Anatomic, Therapeutic, Chemical Classification (ATC) code, 282
animal models
nonclinical testing, 235c
pharmacodynamic testing, 395–396
preclinical device testing, 235c
tissue-engineered product, 495

Annual Safety Reports (ASRs), 311
authorisation procedures for medicinal products
Centralised and Mutual Recognition Procedures for, 278–279
Centralised Procedure, 281–285
Decentralised Procedure, 287–289, 290t
eCTD format and acceptability, 281
legal framework for MAA, 278–279
MA dossier quality section, 280
MA system, 278–279
Mutual Recognition Procedure, 285–287
national authorizations, 289
Notice to Applicants (NTA) for medicinal products, 278–279
referrals, 292, 293
Authorised Representatives, 216, 255–256, 255t

B
Belgium
advertising preapproval, 111
BeNeLuxA, 23
bench testing for devices, 234–235c
bibliographic applications/well-established use, 291–292
biocompatibility testing
nonclinical studies, 234c, 235c
preclinical test plan, 229
requirements from standards and risk management, 230–231
in tissue-engineered products, 465
bioequivalence, 378, 380–381
Biologics Working Party (BWP), 21, 522
biosimilar medicinal products
administration route and dosage parameters, 397
authorised active substance in, 394
clinical comparability demonstration for, 396–397
comparability to reference product, 394–395
comparative development of, 399f
development processes for, 395f, 396f
effects of change to reference product, 399
GLPs for, 396
immunogenicity testing for, 397
MAA data package for, 400t
MAA submission for, 397–398
pharmaceutical regulation evolution, 22
pharmacovigilance and safety reporting, 400
postapproval lifecycle management, 399–400
Index

ATMP MAA timetable, 481–483t
authorisation system, 20
biosimilar medicinal product registration, 397, 401
biosimilar medicinal products, 397
biotechnology-derived product marketing authorisation, 407–408, 413
Brexit effects for UK, 10
combination products, 544
cardiovascular products, 406f
certificate of analysis, 369, 490
cell-based products, 495
Centralised Procedure (CP)
advantages and disadvantages for biotechnology products, 415, 419
advantages/risk comparison for nonprescription medicines, 406t
application evaluation timetable for, 284t
biotechnology-derived products
accelerated assessment procedure, 415
centralised procedure for, 415–416
clinical information, 419
conditional authorisation, 415
development processes for, 394, 416
developmental pharmaceutics, 416
exceptional circumstances application procedure, 415
GLP for preclinical testing, 418–419
MA maintenance, 416
manufacturing information for, 417
pathways to marketing authorisation, 413–414
pharmacovigilance and safety reporting, 419
postapproval lifecycle comparability, 419
postapproval variations, 419
registration procedures for, 414–415
release testing in Europe, 418
TSE and viral clearance data for, 417–418
Blood Products Working Party (BPWP), 522
borderline products classification, 200–201
Brexit. See United Kingdom (UK)
British Pharmacopoeia (BP)
quality systems and inspectorate process, 373
C

carcinogenicity studies, 303
CE Mark
compliance confirmation with, 155
countries requiring, 272
for IVDs, 213–214
central individual case study report (ICSR)
electronic submissions, 449
in PMSF, 440
processing center performance, 441
submission and processing requirements, 443, 445, 445f
centralised marketing authorisation
MAA review for, 53–60
medicinal products, 278–279
Centralised Procedure (CP)
advantages and disadvantages for biotechnology products, 415, 419
advantages/risk comparison for nonprescription medicines, 406t
application evaluation timetable for, 284t
preclinical study program for, 395
registration of, 397–399
safety reporting for, 400–401
therapeutic interchangeability, 22, 399
timeline for development of, 397f
types of biological medicinal products, 393–394
urgent safety restrictions for, 400

Regulatory Affairs Professionals Society
Certificate(s) of Suitability (CEP)
- for APIs, 380
- EDQM issue of, 280, 352
- GMP inspections, 367–369
- registration of medicinal products, 352
- significance of, 369–370

Chemical Abstracts Service (CAS) number, 305

Clinical Effectiveness (EFF) HTA model, 80

Clinical Evaluation Report (CER), 238

Clinical Evaluation Report (CER), 238–240

Clinical Investigation Protocol (CIP), 171, 241

Clinical investigations vs clinical trials
- elements of device evaluation, 238–239
- equivalence to existing device, 239
- GCP and quality in, 241
- objectives of clinical investigation, 239
- performing clinical investigation, 240–241
- planning the evaluation, 239–240
- report required, 238

Clinical Evaluation Report (CER), 238–240

Clinical Investigation Protocol (CIP), 171, 241

Clinical pathway review, 241

Clinical strategy plan, 240

Clinical trial essentials, 241

Clinical trial authorisation process
- amendment notifications, 320–323
- application to national competent authority, 320
- Ethics Committee evaluation and Member State competent authority, 319–320
- Ethics Committee opinion application, 320
- GMO-based products, 463, 497–498

Clinical Trials Directive (CTD), 310–312
- amendment of in-progress clinical trial, 323
- Annual Safety Reports (ASR) requirements of, 312
- application to IMPS, 315–317
- clinical trial end declaration, 323–324
- CTA process and authorisation process, 319–323
- declaring end of clinical trial, 323–324
- ECTR significant changes from, 314–315t
- EudraCT changes, 318–319
- EudraPharm function, 319
- objectives and transition to ECTR, 310, 312
- serious adverse reaction (SAR) reporting, 313

Clinical Trials Facilitation Group (CTFG), 313

Clinical trials for medicinal products, 309–340

Committee for Advanced Therapies (CAT)
- ATMP classification and certification by, 457t, 460, 477, 533
- ATMP Regulation and, 453–457
- combination products, 550, 557
- EMA responsibility for, 164
- feedback during MA review, 54, 55f
- MA evaluation by, 480
- MAA review, 53–54, 54t
- PRAC advise to, 56
- PRIME rapporteur appointment from, 36–37

Index
Committee for Medicinal Products for Human Use (CHMP)

- **ATMP marketing authorisation**, 480
- conditional marketing authorisation grant, 35
- GCP adoption by, 330, 445
- human blood or plasma product regulation, 522, 531
- inspection requests from, 366
- MAA review, 53–54, 54t
- meeting preparation timeline, 57f
- PDCO appointments, 95
- PRAC recommendation endorsements, 119
- responsibilities of, 7

Committee for Medicinal Products for Veterinary Use (CVMP), 8, 366, 555, 557

Committee for Orphan Medicinal Products (COMP), 343

- orphan designation request review, 38
- rare disease designation review, 530
- responsibilities of, 8, 343, 532
- scientific advice from, 37, 48

Common European Submission Portal (CESP), 323–324

Common Specification (CS): GSPRs verifications, 225

Common Technical Document (CTD)

- biotechnology-derived product pharmaceutics, 416–417
- eCTD envelope, 351–352, 352t
- eCTD format and acceptability for medicinal products, 281
- MAA EU format and content, 280–281
- medicinal product registration, 351–352, 351t
- for vaccines, 490

Common Technical Specifications (CTS) for IVDs, 214

Communication and Tracking System (CTS) data base, 288–289

- community interest referral, 293
- competent authorities. See national competent authorities

Competent Authorities for Medical Devices (CAMD), 116, 164

Complete/Full and Independent application, 289

- compliance and postmarket surveillance (devices)
- clinical followup for AIMDs and MDs, 260–261
- Eudamed, 266–267
- feedback mechanisms for, 257–258
- Field Safety Corrective Action (FSCA), 258
- follow-up investigation, 264–265
- FSCAs and FSNs, 265
- **GPSD, MDD, and EU MDR** relationship, 258–259
- incidents and criteria for reporting, 262–264
- medical device global vigilance, 266
- PMS vs vigilance, 266–267
- postmarket surveillance procedures, 259
- risk management in device industry, 260
- surveillance and control provisions, 267–268
- trend reporting, 265

Concerned Member States (CMS)

- application review timeline in, 322
- authorisation of clinical trials under **ECTR**, 324–325
- clinical trial acceptability, 324–325
- clinical trial management and notifications, 328
- clinical trial safety procedures, 323
- clinical trials for medicinal products, 311
- communications with Reference Member State, 355–356
- decentralised procedure applications, 345
- decentralised procedure referral, 293
- decentralised procedures, 288, 355–356
- dossier validation in, 354
- DSUR submission, 333
- IMPD cross-referencing, 330
- inspection report submission by sponsor, 330
- manufacture and importation, 388
- MRP, 356–357
- Mutual Recognition Procedure phase 2 timeline, 286
- national law application in, 337
- RMS evaluation for MA, 19
- scientific advice for IMPs, 324
- scientific advice from competent authority, 322
- sponsor selection of, 345
- vigilance procedures in, 478
- conditional authorisation

- accelerated assessment, 475
- biotechnology-derived products, 415
- by CHMP, 35
- for orphan designation products, 538
- registration of medicinal products, 346

Conformity assessment

- **AIMDD** documentation, 246
- **AIMDD** procedure, 250f
- Authorised Representatives, 216, 255–256, 255t
- CE marking process, 244–245
- Class I device, self-declaration/self-certification, 250f
- Class Ila procedure, 249f
- Class III device options, 248f
- Class IIIlb procedures, 249f
- conformity assessment in, 136
- documentation for, 247
- EC-type examination, 252, 254t
- full quality assurance system, 253, 254t
- high-risk **IVD** procedure, 253f
- internal production control, 252, 254t
- **IVD** procedure, 251f
Index

IVDD Annex II list b procedure, 252f
IVDD documentation, 247t
for IVDs, 216
MDD conformity assessment documentation, 247t
Notified Bodies in, 255
procedures for, 246t
product quality assurance, 253, 254t
product risk class and, 245, 248, 251–252
product verification, 253, 254t
production quality assurance, 252–253, 254t
quality system requirements, 253, 255
self-testing IVD procedure, 251f

Cost and Economic Evaluation (ECO), 80
cost-based pricing (CbP model), 63–64
custom-made devices
Essential Requirements for, 171
EU MDR and EU IVDR, 170–171
medical device legal system, 165–171

D
Danish Centre for HTA (DACEHTA), 78
Danish Promotion Code, 106
Decentralised Procedure (DCP)
applications to other Member States, 286
ATC code and, 282
biosimilar medicinal product registration, 397
biotechnology-derived product marketing authorisation, 413
CMDh, 8, 10
EU regulatory bodies for, 341
flow chart for, 290t
generic medicinal products, 381, 382
human blood/plasma postmarket requirements, 525
human blood/plasma product registration, 523
Information and Work Sharing projects, 386
initial MAA, 356f
market access mechanism, 19, 279, 285, 287–289
medicinal product authorisation procedures, 287–289
medicinal product registration, 344–345, 355–356
nonprescription medicinal products, 405
pathways for nonprescription products, 406f
postauthorisation requirements for pharmaceuticals, 424
referrals, 293
regulatory dossier assessment, 355–356
regulatory information resources for, 554
variation assessment and notifications, 431, 433–434

Declaration of Conformity (DoC)
authorised representative signature, 187
CE Mark for conformity, 155
Essential Requirements for, 213
under EU IVDR, 216
for placing on the market, 170
responsible person for regulatory compliance, 145
See also conformity assessment
Declaration of Helsinki, 311, 390
delegated act definition, 366
Description and Technical Characteristic of Technology (TEC) HTA model, 80
Design Traceability Matrix, 231
Development International Birth Date (DIBD), 333
Development Safety Update Report (DSUR)
contents of, 334t
EVCTM for submission, 335
format for, 443, 444t
ICH guideline for, 312, 332–333
ICH replacement for annual report, 312
Directive defined, 184, 366
Directorate-General for Health and Consumers (DG SANCO), 522
Directorate-General for Health and Food Safety (DG SANTE), 522, 560
divergent decision referral, 293
dossier. See regulatory dossier
Draft Assessment Report (DAR), 355
drug and biologic regulatory pathways
MAA, 32
product development, 31–32
drug product process validation scheme, 351–352
drug-device combination products (DDCs)
classification, 193–194
Drug-Eluting Stent (DES) and medicinal substance, 234–235C

E
electrical magnetic disturbance testing, 233
electrical safety, 233
Electrotechnical Commission (CENELEC), 225
EMA meeting preparation, MAA review
CHMP meeting preparation timeline, 57f
core briefing materials for, 57f
early preparation for, 57
face-to-face meetings, 54–56
Q&A preparation, 58
rehearsals for, 59
rehearsals in Amsterdam, 59
representation and feedback from, 55f
Scientific committee role in, 53
scripting/developing core presentation, 58
slide development and management, 58–59
Standard Assessment Review Timeline, 55f
steps for preparation, 56–57
understand committee members, 57
written briefing document, 58

EMA meetings
advice meetings, 43–44t
communications for MAA, 41–42
general preparation for, 47–48
for MAA, 41–42
MAA procedural steps and, 42–47
during MAA review, 53–60
MAA review, 53–60
scientific advice review, 48
steps required for, 45t
timelines for, 46t
See also specific meeting types

enforcement
CE marking errors, 117
Eudamed communications, 118
medicinal product advertising and promotion, 119–120
medicinal product GMP compliance, 119
medicinal product pharmacovigilance, 119
medicinal products recalls, 119
notified bodies, 118
Safeguard Clause, 117

Enpr-EMA, 101, 559t

Essential Requirements (ER)
clinical investigation vs clinical evaluation, 238–239
compared to GSPRs, 230
conformity assessment for, 187
consensus standards definition by, 225
custom-made devices, 171
GHRF Essential Principles concept, 222–224
harmonised technical standards for, 177
intended purpose and, 167
for IVD manufacturer processes, 211
legal documents, 18
legislative harmonisation and compliance, 155, 213–214
manufacturer GSPR demonstration, 238
safety and performance vs technical
documentation, 23–24

Ethical Analysis (ETH) HTA model, 80–81

Ethics Committees (ECs)
application for opinion on clinical trial, 320
contents of application to, 321t

EU Clinical Trials Register (EUCTR), 319
EU In Vitro Diagnostic Medical Devices Regulation (EU IVDR), 138

EU laws and regulations
basic legislation for, 14

Clinical Trials Regulation (536/2014), 39
codification/clarification of pharmaceutical
directives, 19
CTA, 38–39
current regulation evolution, 17–19
Directive 2001/83/EC, 165, 184
Directive 2004/27/EC, 165
economic issues, 16–17
falsification and counterfeiting, 17
General Data Protection Regulation (GDPR), 138
information availability and transparency, 16
IVDD, 26
medical device regulation evolution, 23–24
medical product regulation development, 14–15
orphan medicinal products (OMPs), 38
Paediatric development programs, 38
Paediatric Regulation, 121
patient advocacy and involvement, 16
pharmaceuticals regulation, 20
PRIME, 36–37
product innovation, 15–16
scientific advice and protocol assistance, 37–38
traditional herbal medicinal products, 23
unsafe product consequences, 15

EU MDR and EU IVDR
ATMPs, 480–484
authorised representative, 173
authorised representative agreement contract forms, 179
classification and conformity assessment, 146
clinical evidence, trials, and regulatory compliance, 144–145
clinical investigation devices, 171
Commission recommendation, 174, 174t
custom-made devices, 170–171
delegated and implementing acts, 148
EC working groups, 165, 166–167t
Essential Requirements vs GSPRs, 238
governance structure, 147–148, 147f, 176f
healthcare establishments, 164
human tissues, cells and derivatives, 484
implementation of MAID goods package, 142–143
implications of, 148–149
importers and distributors, 164
improved elements, 173–174
industry representation/trade associations, 165, 167t
institutional cooperation and consensus
building, 164–165
interpretation of device law
Commission as an arbitrator, 177
Commission guidance, 175–176
courts, 174
guidance from Member States, 177
guidance from other sources, 177
key directives, 165
legal system evolution, 178
manufacturer, 171–173
manufacturers and authorised representatives, 164
market access mechanism, 144
MDD and EU MDR device definitions, 168t
MEDDEV guidance documents, 172–173t
medical devices and active implantable medical devices, 142, 165–170
national enforcement, 177–178
NBOG Best Practice Guide, 175t
notified bodies changes with, 144
overview, 180
own-brand labelling and reprocessing, 146–147
postmarket surveillance and vigilance, 145–146
product liability, 178–179
proposed IVDR classification rules, 145f
scope of device directives, 165
significance of technical standards, 177
stakeholders, 159
supply chain controls, 142f
supply chain vigilance obligations, 179–180
timeline for adopting/transitional regime, 148
traceability, 143–144
EU MDR and EU IVDR
ISO 13485 in transition to, 255
QMS requirements and ISO 13485, 252–253
EU Medical Devices Regulation (EU MDR), 480–481
EU regulatory affairs
adaptive and alternative pathways, 295–300
advertising and promotion, 103–114
ATMP regulatory framework, 451–470
biosimilar medicinal products, 393–402
clinical evaluation and clinical investigations, 237–242
combination products, 543–552
drug and biologic regulatory pathways, 31–40
EMA and other regulatory bodies, 1–12
enforcement and competent authorities, 115–120
Falsified Medicines Directive (FMD), 121–134
food for special medical purposes, 511–518
food supplements, 501–510
generic medicinal products, 377–392
Health Technology Assessment (HTA), 77–92
history of regulations, 13–30
human blood or plasma products, 519–528
human tissue regulation, 471–488
MAA for biotechnology derived products, 413–422
Marketing Authorisation Application (MAA) review, 53–60
Marketing Authorisation Application (MAA) submissions, 41–52
medical device compliance/postmarket requirements, 257–269
medical device conformity assessment procedure, 243–256
medical device legislation and classification, 183–206
medical device national particularities, 271–276
medical device preclinical testing, 229–236
medical devices legal system, 151–182
medicinal product authorisation procedures, 277–294
medicinal product clinical trials, 309–339
medicinal product registration procedures, 341–362
new MDR and IVDD regulation, 141–150
nonprescription medicinal products, 403–412
orphan medicinal products (OMPs), 529–542
Paediatric Regulation, 93–102
pharmaceutical postauthorisation requirements/compliance, 423–436
pharmaceutical quality systems and inspectorate process, 363–376
pharmacovigilance, 437–450
preclinical testing and GLP, 301–308
pricing and reimbursement, 61–76
regulatory information resources, 553–573
regulatory strategy, 135–140
safety and performance requirements/technical documentation, 221–228
vaccines, 489–500
in vitro diagnostic devices (IVDDs), 207–220
EU Tissue and Cell Directives (EUTCD), 471–473. See also specific tissue and cell products
EU Treaty, 14
Eudamed
competent authority communications, 118
market surveillance and vigilance, 267–268
EudraVigilance databases, 318, 566
EudraCT paediatric clinical trial records, 319
EudraGMDP inspection information in, 369
EudraVigilance Clinical Trial Module (EVCTM), 332, 335
EudraVigilance medicinal product dictionary (xEVMPD), 440
EudraVigilance Postauthorisation Module (EVPM), 493
Eurasian Economic Union Member States, 374
European Association of Tissue Banks (EATB), 473
European Blood and Marrow Transplantation Group (EBMT), 473
European Clinical Trial Database (EudraCT) clinical trial databases, 38, 100
SUSAR reporting, 318
European Clinical Trial Regulation (ECTR)
   adverse reactions in, 313
   application to IMPs, 315–317
   electronic reporting, 319
   EU Clinical Trials Register (EUCTR), 317–318
   EU Portal, 317
   EU portal and database, and associated legacy
   systems, 311
   EU Telematics Strategy and Implementation
   Roadmap, 317
   EudraVigilance Clinical Trial Module (EVCTM),
   317–318
   evaluation for duplication, 318
   implementation guidance documents, 312–313
   Member States national laws and, 311
   significant changes from Clinical Trials Directive,
   314–315

European Community (EC)
   demonstration of GSPRs, 225
   initiatives and models for pricing, 63–64
   Notice to Applicants (NTA) for medicinal products,
   278–279
   regulatory authorities, pharmaceutical quality,
   365
   Task Force for Relations with the United Kingdom
   (UKTF), 364, 366

European Economic Area (EEA)
   CE marking requirements, 272
   European Eye Banking Association (EEBA), 473
   European Federation of Pharmaceutical Industries
   and Associations (EFPIA)
   CE marking requirements, 272
   codes of conduct, 104–105
   falsified medicines legislation, 123
   product distribution, 106–107, 111
   regulatory information from, 564
   European Food Safety Authority (EFSA)
   food supplement assessment by, 504–505
   foods for special medical purposes, 513–514
   scientific advice, 560
   European Generics Medicines Association (EGA),
   379
   European Initiative for Paediatric Formulations
   (EuPFI), 100
   European Medicines Agency (EMA)
   accelerated access initiatives, 295–300
   early access initiatives, 88–89
   EUnetHTA collaboration, 88–89, 88f
   falsified medicine defined, 121
   HTA parallel consultation, 88
   marketing recommendation for medicinal
   products, 278–279
   regulatory authorities, pharmaceutical quality,
   365
   European Medicines Verification Organisation
   (EMVO), 131
   European Medicines Verification System (EMVS), 131
   European Network for HTA (EUnetHTA)
   EMA collaboration, 88–89
   HTA assessments, 78–88
   MAA evaluation, 50, 65–67
   European Network of Centres for
   Pharmacopoeiology and Pharmacovigilance
   (ENCePP), 445–446
   European Pharmacopoeia (Ph. Eur.), 373
   European Public Assessment Report (EPAR), 283,
   398–399
   European Society of Human Reproduction and
   Embryology (ESHRE), 473
   European Standardization Committee (CEN), 225
   European Transplant Coordinators Organisation,
   473
   European Union (EU)
   medical product regulatory bodies, 341–342
   pricing and reimbursement, 61–76
   European Union Reference Dates (EURD)
   active substances, 388
   PSURs and PSUSAs scheduling, 360, 445
   exceptional circumstances
      medicinal product registration, 366–367
      for orphan designation products, 538–539
   expedited evaluation programs
      ATMPs, 453
      decision tree for pathways, 454
      See also Adaptive Pathways; alternative
      pathways; PRIME (PRIority MEdicines)
   External Reference Pricing (ERP)), 63, 64f. See also
   pricing and reimbursement

F
   facility requirements
      medicinal requirements, 305
   Falsified Medicines Directive (FMD), 121–134
      active substance GMP, 128
      active substances and excipient definitions, 128
      combination therapies, 132
      companion diagnostics, 132
      defining, 122
      detection and management goals of, 132
      EMVS in, 131–132
      examples of SFFC medicines, 126
      falsified active substances in routes in supply
chain, 125f
harmonisation of regulation, 124
implementation of, 124–125
implementation process for, 128–129
implications and challenges of, 129–131
initiatives relevant to, 129t
key term definitions, 124t
online logo requirements, 128f
problem scope, 122
stakeholder requirements, 124
stakeholder requirements under FMD, 127t
third countries requirements under, 125, 128, 129t
unique product identifiers and information flow, 131f
Field Safety Corrective Action (FSCA), 258
Field Safety Notices (FSNs), 265
first-in-human (FIH) trials guidance documents, 322
follow-up referral, 292
Food and Drug Administration (FDA)
collaboration on paediatric products, 100
PSA for MAA/EMA meetings, 49
Food for Special Medical Purpose (FSMP) Regulation, 512–513
food for special medical purposes (FSMPs) communications and claims for, 516
competent authority notification of marketing, 516
compositional requirements for, 514–515
definition of, 513
food information and nutrition information, 515–516
FSMP critical concepts, 513–514
history of use, 511–512
legal framework for regulation, 512–514
reimbursement, 516
single-use plastics directive for, 516
food supplements, 501–510
competent authority notification of marketing, 504
for food supplements, 505–507
harmonisation of, 507
health claims for, 505
labelling (information to consumers), 503–504
legal framework for regulation, 505–507, 512–513
quality requirements, 503
regulatory summary, 507–508
safety assessment of ingredients, 504
scope and definitions for regulation, 502–503
vitamin/mineral content for safety, 504
Food Supplements Directive (FSD), 502–504
generic medicinal products, 377–392
advertising and promotion, 389
biosimilar applications, 383
biosimilar medicines, 380
comparison with innovator medicines and reference products, 377–378
compendial monographs for, 380
dossier requirements for, 383–386
electronic submission of information for, 390
GCP for, 390
GDP for, 389, 390
GLP for, 390
GMP for, 389–390
Good Pharmacovigilance Practices for, 386–387, 390
Gene therapy medicinal products (GTMPs) clinical development, 466
decision tree for classification, 459f
intended use and manipulation criteria, 461
manufacturing process, 461–463
preclinical development, 464–465
General Electrical Safety Standard, 233
General Product Safety Directive (GPSD), 259
general safety and performance requirements (GSPRs)
applicable standards identification, 226
checklist for, 223–224
device registration requirements, 216
historical foundations for, 221–222
IVDD revision by EU IVDR, 216–217
manufacturer GSPR demonstration, 187, 238
predicate device requirement, 227
referencing applicable standards, 227
regulatory status of European standards, 225
requirements for, 222, 223
standards and common specifications use for, 225
technical documentation, 226–227
terminology change, 238
general principles of regulation, 512
for specific groups, 512
Foods for Specific Groups (FSG) Regulation, 512–513, 516
France
advertising preapproval, 111
HTA in, 82t, 83t
HTA process in, 85f
pricing/reimbursement procedures, 68–69
pricing/reimbursement-HTA assessment competent authorities, 68
Universal Health Coverage Act (CMU), 67
G
gene therapy medicinal products (GTMPs) clinical development, 466
decision tree for classification, 459f
intended use and manipulation criteria, 461
manufacturing process, 461–463
preclinical development, 464–465
General Electrical Safety Standard, 233
General Product Safety Directive (GPSD), 259
general safety and performance requirements (GSPRs)
applicable standards identification, 226
checklist for, 223–224
device registration requirements, 216
historical foundations for, 221–222
IVDD revision by EU IVDR, 216–217
manufacturer GSPR demonstration, 187, 238
predicate device requirement, 227
referencing applicable standards, 227
regulatory status of European standards, 225
requirements for, 222, 223
standards and common specifications use for, 225
technical documentation, 226–227
terminology change, 238
generic medicinal products, 377–392
advertising and promotion, 389
biosimilar applications, 383
biosimilar medicines, 380
comparison with innovator medicines and reference products, 377–378
compendial monographs for, 380
dossier requirements for, 383–386
electronic submission of information for, 390
GCP for, 390
GDP for, 389, 390
GLP for, 390
GMP for, 389–390
Good Pharmacovigilance Practices for, 386–387, 390
GPMs for, 379–380
international regulations for, 386
labelling and package leaflet, 388–389
legal basis for generic application for MA, 381–383, 381t
manufacture and importation for, 388
postauthorisation surveillance of, 380
PSURs for, 387–388
RMP for, 387
supervision and sanctions for, 390–391
WHO definition of, 377
wholesale distribution of, 389
genetic/Abridged application, 289–290
genetically modified organisms (GMO)
GTMPs, 463
vector use in, 497–498
genotoxicity studies, 303
Germany
competent authorities for pricing//reimbursement and HTA, 69
Gesetzliche Krankenversicherung (GKV), 69
HTA in, 82t, 83t
HTA process in, 86f
medicinal product pricing under AMNOG, 70f
pricing/reimbursement procedures, 69–71
Safeguard Clause action (catgut), 267
Global Harmonization Task Force (GHTF)
Essential Principles concept, 222
guidance document from, 240
IMDRF succession to, 266
IVD risk classification of IVDs, 212–213
risk-based device classification, 206
STED developed by, 226
See also International Medical Device Regulators Forum
Good Clinical Practice (GCP)
biological product guidance, 490
biosimilar clinical comparability demonstration for, 396–397
biotechnology-derived products, 416
clinical investigation of devices, 240–241
in drug life cycle, 364
for generic medicinal products, 390
legal framework and, 370–371
Good Distribution Practice (GDP)
in drug life cycle, 364
for generic medicinal products, 389, 390
inspections for, 371
Good Laboratory Practice (GLP)
ancillary quality system components, 306
for biosimilar medicinal products, 396
biotechnology-derived products, 416
definition, 301
in drug life cycle, 364
facility requirements, 305
for generic medicinal products, 390
inspections and compliance, 307
medicinal product requirements, 302
pharmacokinetic studies in vitro, 302–303
pharmacology safety studies, 302
preclinical studies required by, 302–303
products covered, 304
purpose and relevance guidance, 306–307
Quality Assurance programme, 305
regulations and guidelines for toxicity studies, 302
reporting study results
content of study plan, 306
revisions for harmonisation, 307–308
SOPs for test facility, 306
study performance
study plan and content, 306
test and reference items
characterization, 305–306
receipt, handling, sampling and storage, 305
test facility organisation
management, 304
principal investigator, 305
study director, 304–305
test systems, 305
in vivo feasibility and dose testing under, 303
Good Manufacturing Practice (GMP)
biotechnology-derived products, 416
certificate, 119, 369, 390–391
in drug life cycle, 364
foods for special medical purposes, 512
for generic medicinal products, 389–390
for herbal medicines, 410
MAH compliance, 119
Good Pharmacovigilance Practices (GVPs)
for biosimilar medicinal products, 400–401
in drug life cycle, 364
for generic medicinal products, 390
GVP overview and modules, 439–449, 439t
MA maintenance, 360
Module I: PV systems and quality systems, 439–440
Module II: PV system master file, 440
Module III: PV inspections, 440–442
Module IV: PV audits, 442–443
Module IX: signal management, 446–447
Module V: risk management systems (RMS), 443
Module VI: adverse reaction management/reporting, 443
Module VII: PSURs, 443–445
Module VIII: post authorisation safety studies, 445–446
Module X: additional monitoring, 447–448
Module XV: safety communications, 448
Module XVI: risk minimisation measures, 448–449
nonprescription medicinal products, 409

Guidance documents
European Commission Consensus Statements, 174t
European Commission documents, 174t, 175–176
MDCG, 185
MEDDEV Commission guidance, 172–173t
NBOG Best Practice Guide, 175t
TEAM-NB, 177

H
harmonisation
EURD in, 388
of food supplements, 507
GLP regulations, 307–308
GSPR compliance demonstration, 225–226
medical device regulation, 24–25
of SmPC, 342, 345
standards for IVDs, 213–216
Heads of Medicines Agencies (HMA), 311
Health Claims (HCs)
food supplements, 505–506, 507
foods for special medical purposes, 513, 516
health monitoring measures
actions against general threats to public health, 117
comparison with Safeguard Clause, 267–268, 267t
Health Problem and Current use of Technology (CUR)
HTA model, 80
Health Technology Assessment (HTA), 77–92
comparison in EU countries, 81–84, 83t
decision timeline, 87t, 88f
EMA and EUnetHTA collaboration, 88
harmonisation, 84–88
HTA in Member States, 82t
legal framework, 77–78
models used for: CUR, 80
models used for: ECO, 80
models used for: EFF, 80
models used for: ETH, 80–81
models used for: LEG, 81
models used for: ORG, 81
models used for: SAF, 80
models used for: SOC, 81
models used for: TEC, 80
organisation and structure in EU, 81–84
parallel advice for MAA, 49–51
pricing and reimbursement, 65–66
role in decision making, 84

role in product market, 78–80
heated sleep apnea device, 234c
herbal medicinal product MAA, 292
human blood or plasma products, 519–528
batch-release requirements, 525
CHMP working groups, 522
Council of Europe publications on, 523
DG SANTE, 522
donation testing for, 523–524
guidelines and documents for, 523–524
legal framework, 522–523
marketing authorisation dossier for, 524–525
plasma master file, 525
plasma-derived medicinal products, 520–521, 521t
postmarketing pharmacovigilance for, 525
registration procedures for, 523
Single European Code structure, 476t
transition to new regulations, 525–526
TSE safety evaluation, 524
virus safety evaluation, 524
Human Organ Transplantation Directive, 485
human tissue products, 471–487
ATMP classification, 477
classification of, 477–478
contiguous legislation, 484–485
distribution and import, 476
donation of, 474
donor selection and testing, 474–475, 475t
EUTCD requirements, 473–474
legislation on, 473–474
licensing and inspections, 478
MA authorisation for, 480
MA procedure for, 480
as medical device, 483
pharmacovigilance (PV), 477–478
processing and storage, 475–476
procurement, 474
quality system for establishment and responsible person, 478–479
regulation, 473, 480–484
regulatory framework for, 484t
responsible person qualifications/responsibilities, 479t
tissue establishments and banks, 478
traceability, 476–477
hybrid applications, 291

I
Identification of Medicinal Products (IDMP), 359
immunogenicity data
advanced therapy medicinal products, 465
biosimilar medicinal product development, 395
biotechnology-derived products, 417–419
comparability exercise for biosimilars, 396–397, 398
pre-licensing product testing, 349
vaccines, 494, 496
immunotoxicity studies, 303
Impact on Clinical Research of European Legislation (ICREL), 310
Importing Directive, 485
In Vitro Diagnostic Medical Devices Regulation (EU IVDR), 141–149, 189–200
in vitro diagnostic (IVD) medical device, 207–220
accessories, 210
classification disputes, 203
classification process, 201–203
companion diagnostic (CoDx), 211–212
device performance testing, 210
essential requirements for, 213
EU laws and regulations, 26
in-house developed, 211
IVD use, 209
IVDD and IVDR classification rules, 204–205
IVDD and IVDR scope, 208–209
IVDD revision, 216–217
laboratory use products and IVD devices, 210t
manufacturer process, 211
medical device legislation and classification, 208–209
pan-European requirements, 207
regulations for safety, 217
research-only, 210–211
risk-based classification lists for, 212–213
specimen receptacles, 209–210
specimens examined, 209
In Vitro Diagnostic Medical Devices Directive (IVDD), 184–185
In Vitro Diagnostic Medical Devices Regulation (EU IVDR), 189, 544
influenza vaccines, 494–495f
Information and Work Sharing projects, 386
informed consent applications, 292
in-house produced devices, 147
innovator medicines (originator products), 378–379
inspection process
in drug approval process, 367f
EudraGMDP database entries, 369
GLP regulations, 307
pharmaceuticals, 366–369
tissue establishment inspections, 478
installation qualification (IQ), 306
Instructions for Use (IFU)
contents for IVDs, 215
device evaluation and, 238
international birth date (IBD), 333
International Coalition of Medicines Regulatory Authorities (ICMRA), 374–375
International Conference on Harmonisation (ICH)
coordination and cooperation enhancement, 117
Development Safety Update Report, 312
guidelines for biotechnology-derived products, 416–417
harmonisation of preclinical testing, 302
pharmaceutical quality systems, 365
PSUR format revision and scheduling, 445
International Electrotechnical Commission (IEC)
medical device standards, 230–231, 233–234
standard use in EU, 164, 177
International Federation of Pharmaceutical Manufacturers Association (IFPMA)
code of ethics, 103, 105, 107
promotional material approval, 111
International Generic Drug Regulators Pilot (IGDRP), 386
International Medical Device Regulators Forum (IMDRF)
consensus standards, 225–226
coordination and cooperation enhancement, 117
GHTF basis for, 266
inspection guidelines, 374
medical device global vigilance, 266
International Medical Products Anti-Counterfeiting Taskforce (IMPACT), 122, 123t
International Organization for Standardization (ISO)
consensus standards definition by, 225
standard harmonisation, 164, 561
use in preclinical testing, 230
See also specific standards
International Society of Pharmacoepidemiology (ISPE), 374, 445
invasive devices: classification rules for (MDR), 190t
Investigational Medicinal Product Dossier (IMPD)
biological product guidance, 490
content requirements for, 490
submission, 330–331
investigational medicinal products (IMPs), 317
Clinical Trials Directive definition of, 315
clinical trials for, 310
CTD information in dossier, 330
documentation requirements for, 490
DSURs for, 332
for FIH trials, 322
GMP requirements for, 331
manufacturing requirements for, 498
risk-benefit amendment notification, 322
SUSARs/DSURs for, 332
ISO 13485
gap assessment for EU MDR and EU IVDR transition, 255, 258
Index

harmonised quality system model, 214–215, 226
production quality assurance model, 252–253
QMS requirements, 215
review of feedback, 259, 266, 268
ISO 14971
FSCA warning methods, 265
harmonised standards for risk management, 214
postmarket surveillance and vigilance, 258
risk management requirements, 226, 266, 268
Italian Farmaindustria Code, 106
Italy
advertising preapproval, 111
competent authorities for pricing/reimbursement and HTA, 72
HTA in, 821
pricing/reimbursement procedures, 72–73
Servizio Sanitario Nazionale (SSN), 72

J
Joint Action on Market Surveillance (JAMS), 3, 116
Joint Immediate Action Plan, 118

L
labelling requirements
combination products, 551
food for special medical purposes (FSMPs), 515–516
for food for special medical purposes (FSMPs), 516
food supplements, 503–504
language for IVDs, 215–216
Legal Aspects (LEG) HTA model, 81
legal framework/legislation
for adaptive and alternative pathways, 296–298
Advanced Therapy Medicinal Products (ATMPs), 451–470, 480
ATMP Regulation, 453–456
clinical trial improvements, 312f
clinical trials, 311
Directive defined, 184
for food supplements, 505–507
foods for special medical purposes and special groups, 512–514
herbal medicinal products, 409–410
human blood or plasma products, 522–523
human tissue products, 473–474
MAA, 32–34
mechanism for medicinal products for human use, 18–19
medical devices, 141–149, 150–182, 183–206
medical product, 18
Opinion, 184
orphan medicinal products, 530
pharmacovigilance (PV), 438–439
product legislation, 17–18
Recommendation, 184
Regulation defined, 184
lifecycle of drugs
regulations in, 364f
research and development (R&D), 22–23
local tolerance studies, 303

M
Market Surveillance Operations Group (MSOG), 267
Marketing Authorisation Application (MAA)
accelerated assessment for, 35
approval types, 34, 36t
for biosimilar medicinal products, 397–398
for biotechnology derived products, 292
clarification and discussion meetings, 54–55
communications to EMA, 41–52
dossier quality section, 280
EMA meetings during review, 53–60
EU format and content of, 280
human-veterinary variations, 20–21
legal basis and dossier requirements, 32–34
legal basis for generic application for MA, 381–383
medicinal product application types, 289–292, 290t, 291–292
for medicinal products, 279–284
PIP requirements, 94–95, 98–100
prior EMA meetings for, 41–52
procedural steps and EMA meetings, 42–47
procedure timelines for, 55f, 57f
procedures for, 34–35
scientific advice and protocol assistance, 37–38
Scientific Advice review, 54
Scientific committee role in review, 53, 54t
Marketing Authorisation Holder (MAH)
advertising to general public, 108
advertising to healthcare professionals, 105
definition of, 279
EMVO, 119
GMP compliance, 119
MA maintenance, 359
obligations for medicinal products, 282, 284, 289
paediatric products, 99–100
PIP preparation, 94–95
product failure responsibility and liability, 342
renewal date agreement with Reference Member State, 424
responsibilities and obligations for medicinal products, 279–280
role in various application types, 292
scientific service implementation, 111
submission of information for generic products, 390
worksharing, 359
Marketing Authorisation (MA)
adaptive and alternative pathways, 295–300
food supplements, 504
for generic medicinal products, 391
human tissue products, 480
regulatory strategy for, 138
See also Centralised Procedure; Mutual
Recognition Procedure; National Procedure
maximum tolerated dose (MTD), 302
MEDDEV guidance documents
authorised representatives, 143
clinical evidence, trials, and regulatory
compliance, 144, 146
revisions and updates, 118
Medical Device Coordination Group (MDCG)
borderline combination products, 545
centralised governance, 159, 165
classification disputes, 203–205
CTS adoption by implementing act, 214
decisions on product qualification, 142
device classification determination, 142
enforcement and surveillance, 146–148, 159, 178
regulatory classification determination, 545,
548–549, 551
regulatory strategy development, 138
regulatory strategy information, 138
responsibilities of, 176–177
revised guidance from, 230
Medical Devices Directive
repeal of, 184–185
transition from, 178 (see also EU MDR and EU
IVDR)
medical device legal system
adaptive and alternative pathways, 298
clinical evaluation cycles, 159f
Commission as an arbitrator, 177
compliance verification, 155
certainty assessment for AIMDs, 157f
certainty assessment for IVD, 158f
certainty assessment procedures, 156f
custom-made devices, 165–171
development, 25–26
EC working groups and activities, 166–167t
EMA in, 164
enforcement, 117
enforcement and competent authorities, 117–118
Essential Requirements and technical standards, 177
esential requirements compliance, 155–159
industrial trade associations, 167t
legislative process, 150–152, 153f
manufacturer role in, 171
market surveillance, 117–118
MDD and EU MDR device definitions, 168t
MEDDEV guidance documents, 171–172t
medical device laws, 165–170
national enforcement, 177–178
new approach regulatory philosophy, 153–154, 154t
new legislative framework (NLF), 157
regulation evolution and harmonisation, 23–25
See also EU MDR and EU IVDR; specific devices
medical device legislation and classification, 183–206
basic principles of application, 189–190
classification disputes, 203
classification matrix, 188t
comparison of EU MDR and MDD rules, 195–200t
EU MDR and MDD rules, 200–201
human tissue/cell products with, 483
IVD classification process, 201–203, 202t
IVDD and IVDR rule comparison, 204–205t
key concepts for classification, 191, 193
MDR rules for invasive devices, 190t
MDR rules: special, 192t
medical devices directives, 184–185
medical devices definition and expansion of, 185–186
non-invasive devices rules, 189t
regulatory framework definitions, 184
requirements, 186–187
rule-based approach for, 187–189
transition to EU MDR and EU IVDR, 185
unclassified devices, 188
in vitro diagnostic regulation, 189
medical device national particularities
CE marking for, 271
directives and regulations for, 272t
EU outermost regions, 272t
language and labeling, 272–274
national languages, 274t
notification requirements, 274–275
translation requirements, 273t
See also pricing and reimbursement
Medical Device Vigilance System, 258, 261
Medical Devices Coordination Group (MDCG), 159
Medical Devices Regulation (EU MDR), 141–149
Medicinal Product Directive (MPD), 18, 32, 506
medicinal products for human use
adaptive and alternative pathways, 296–298
bibliographic applications/well-established use, 291–292
clinical trials for, 309–340
Complete/Full and Independent, 289
Index

decentralised procedures, 290t
enforcement, 119–120
enforcement and competent authorities, 118–120
factors affecting pricing, 62f
fixed-combination application, 292
generic/Abridged, 289–290
herbal medicinal products, 292
hybrid applications, 291
informed consent applications, 292
legislation in EU, 18–19
Marketing Authorisation Application, 289–292
mixed marketing, 292
medicinal products MAA applications bibliographic applications/well-established use, 291–292
Complete/Full and Independent, 289
decentralised procedures, 290t
fixed-combination application, 292
generic/Abridged, 289–290
herbal medicinal products, 292
hybrid applications, 291
informed consent applications, 292
mixed marketing, 292
Medicines and Healthcare products Regulatory Agency (MHRA)
joint inspection programs, 372–373
Medicines for Europe, 379
Member States
clinical trial authorisation procedures in, 324
clinical trial safety procedures, 323
competent authorities and affiliated countries, 161–163t
competent authorities marketing guidelines, 278–279
enforcement by competent authorities, 115–120
EU MDR and ER IVDR significance for, 159–164
GLP regulations in, 302
interim device actions under Safeguard Clause, 267
Marketing Authorisation Application in, 19
See also Concerned Member States; national competent authorities
mixed marketing, 292
Mutual Acceptance of Data (MAD) system, 302, 370
Mutual Recognition Agreements (MRAs)
for generic product GMP inspections, 379–380
for inspections, 371
Mutual Recognition Facilitation Group (MRFG), 286
Mutual Recognition Procedure (MRP)
application format for, 281
authorisation of medicinal products, 285–287
biosimilar medicinal product registration, 381
biotechnology-derived product marketing authorisation, 413
comparison of pathways for nonprescription products, 406f
criteria for use of, 19, 285
evaluation of products, 14
flowchart for, 287f
for generic products, 381
human blood/plasma postmarket pharmacovigilance, 525
MAA procedure with, 357f
medicinal product registration, 341
for medicinal products, 287t
multiplication/duplication of applications, 289
nonprescription products, 405
phases and timeline for medicinal products, 285–287
postauthorisation requirements for biotechnology products, 424–425
product registration, 356–357
Reference Member State selection, 287–288
registration for human blood/plasma products, 523
registration for medicinal products, 289, 345, 356
regulatory dossier assessment, 356–357
regulatory information resources for, 554
submissions and Reference Member State role and timeline, 286–287
Mutual Recognition Regulation, 502–503, 506
mutual recognition/decentralised procedure referral, 293

N
national authorizations, medicinal products, 289
national competent authorities, 115–120
action on medical device safety, 117–118
application for clinical trial authorisation, 320–323
clinical trial application, 321t
cooperation and coordination for enforcement, 116–117
coordination and cooperation enhancement, 117
generic medicinal product safety, 390–391
inspection process, 366
listing of, 562–563t
medical devices, 117
member states and affiliated countries, 161–163t
national regulatory bodies, 116
pharmaceutical quality and inspections, 365–369
pricing and reimbursement and HTA, 366
tissue establishment inspections, 478
National Medicines Regulatory Authorities (NMRA), 130
National Medicines Verification Organisations
Index

(NMVOs), 132
National Procedure
  biosimilar medicinal product registration, 397
  comparison of pathways for nonprescription products, 406f
  generic medicinal products, 381
  human blood/plasma products, 523
  MAA procedure with, 357f
  marketing authorisation for medicinal products, 19
  medical product registration, 345–346
  medicinal product registration, 357
  nonprescription medicinal products, 405
  product registration, 345–346, 356–357
  regulatory dossier assessment, 357
  variability of, 285
new chemical entity (NCE): preclinical test plan, 302
new legislative framework (NLF) for devices, 157
nonclinical pharmacodynamics, 235c
nonclinical studies. See Good Laboratory Practice; preclinical testing
non-invasive devices: classification rules for (MDR), 189t
noninvestigational medicinal products (NIMPs)
  defined, 315
  SUSARs for, 332
nonprescription medicinal products, 403–412
  advertising and promotion, 408–409
  advertising to general public, 409
  common uses of, 405t
  definition of, 404
  herbal medicinal products, 409–410
  legal basis of MAA, 405
  legislation of, 404
  marketing access pathways for, 404–405, 406t
  pharmacovigilance and safety reporting, 409
  product information and labelling, 405–407
  reclassification from prescription to, 407–408
  role in self-care, 404
  successful switch strategy for, 408
  warning statements and guidance for, 407
Notified Bodies: responsibilities of, 118
Notified Body Operations Group (NBOG)
  best practices guides, 175t
  guidance document from, 175, 185–186
Novel Foods Regulation, 504
Nutrition and Health Claims Regulation (NHCR)
  (Regulation (EC) No. 1924/2006), 505
Nutrition Claims (NCs), 505

O
office based evaluation and risk assessment (OBERA), 371
Official Control Authority Batch Release (OCABR)
  batch-release requirements, 493
  EDQM procedures for, 522
  plasma products, 525
Official Medicines Control Laboratories (OMCL)
  blood/plasma product testing, 522
  postmarketing lot release, 493
  vaccine testing by, 490
operational qualification (OQ), 306
Opinion, defined, 184
Oral Explanation (OE) meeting
  purpose of, 55
Organisation for Economic Co-operation and Development (OECD)
  EMA collaboration, 10
  GLP guidelines, 327, 375, 390
  harmonisation of preclinical testing, 302–304
  mutual acceptance of data system, 370
Organisational Aspects (ORG) HTA model, 81
Orphan Drug Act, 529
Orphan Medicinal Products (OMP) Regulation
  COMP established by, 531–532
  product designation procedure, 535
  significant benefit concept in, 536–537
  similar medicinal product and clinical superiority in, 537
orphan medicinal products (OMPs), 529–542
  annual report requirement, 534
  application evaluation and timetable for, 533
  conditional marketing authorisation for, 538
  designation expiry, 535
  designation procedure application, 532–533
  designation request content, 535–536
  EU laws and regulations, 38
  European Commission decision, 533–534
  harmonisation efforts, 530
  incentives for development, 530–531
  legal framework, 530
  MAA for designation product, 536–537, 538
  medical plausibility for request and prevalence, 536
  orphan designation benefits, 342
  orphan designation benefits and criteria, 8, 38, 530, 534f
  parallel applications, 533
  pathways for expedited development and approval, 538
  significant benefit concept in, 536–537
  similar medicinal product and clinical superiority in, 537
  sponsorship transfer, 535
over-the-counter (OTC) medicines. See nonprescription medicinal products advertising to general public, 108
Own-Brand Labelling (OBL), 146–147

P

Paediatric Committee (PDCO), 95, 343
Paediatric Investigation Plan (PIP)
  Marketing Authorisation Holder, 94–95
  submission procedures in, 97–99, 98f
paediatric product regulation
  application procedure, 97–99
  background and scope, 93–94
  compliance check, 99
  deferrals, 96–97
  Marketing Authorisation Holder, 99–100
  PDCO, 95
  PIPs, 94–95
  population and product definitions, 94
  product development under, 100–101
  research incentives, 99
  waivers, 95–96
Paediatric Regulation, 93–94
Paediatric Use Marketing Authorisation (PUMA), 94
Parallel Scientific Advice (PSA), 49
particular nutritional uses (PARNUTs), 512
Patients and Social Aspects (SOC) HTA model, 81
performance qualification (PQ), 306
Periodic Benefit-Risk Evaluation Report (PBRER)
  EU format for, 445
  format for, 443, 444t
  ICH guideline for, 445
Periodic Safety Update Report (PSUR)
  benefit-risk balance, 387–388, 401, 425–426, 449
  for biosimilar medicinal products, 401
  device technical documentation, 227
  frequency of, 416
  MAH submission of, 443
  PMCF in, 261
  postmarketing safety assessment, 425, 428, 429
  PSUR format revision and scheduling, 445
  renewal procedures and, 436
  requirements for, 440
  RMP update, 447
  sharing through Eudamed, 118
  submission and review process for, 360
  submission of, 443–445
  submission to EMA, 353
  synchronization with other reports, 333, 426, 445
  for technical documentation, 227
  validated signals in, 447
Periodic Safety Update Single Assessment (PSUSA)
  submission to EMA, 353
pharmaceutical directives
  ATMPs, 21–22
codification/clarification, 19
development of regulatory system, 20
human-veterinary MAA variations, 20
Pharmaceutical Inspection Convention (PIC), 117, 373
Pharmaceutical Inspection Co-operation Scheme (PIC/S)
  for generic products, 379–380
  participants in (list), 373–375
pharmacodynamic (PD) testing: biosimilars, 395
pharmacokinetic (PK) testing
  for biosimilar medicinal products, 395
  with combination product, 235c
pharmacovigilance (PV)
  EC definition and development of, 438
  fees, 449
  GVP overview and modules, 439t
  human tissue products, 477–478
  ICSR expedited submission requirements, 445f
  legal framework, 438–439
  notification of withdrawn products, 449
  risk management plan modules, 444t
  signal management lifecycle, 447f
  system master file (PSMF) contents, 441f
vaccines, 493
Pharmacovigilance Regulation, 493
Pharmacovigilance Risk Assessment Committee (PRAC)
  communications, 66
  coordination and cooperation enhancement, 117
  MA maintenance, 360
  MAA review, 53–54, 54t
photo-safety testing, 303
Plasma Master File (PMF), 280
plasma master file (PMF), 280, 525
Post Market Clinical Follow-up (PMCF), 238
postauthorisation requirements (pharmaceutical)
  annual re-assessment
    assessment procedures, 431
    dossier requirements for, 430–431
  for biotechnology-derived products, 424–425
  centrally approved product renewal
    assessment procedure, 429–430
    dossier requirements for, 426
  legal framework for, 421, 424–425
  major changes/extension application, 435
  MRP/DCP product renewal, 424–425
  assessment procedures, 426
  dossier requirements for, 425
  other postauthorisation measures and enforcement, 431
  re-examination, 430
vaccines, 492–493
variations
assessment/notifications for, 433–435
dossier requirements for, 431–433
postauthorisation safety studies (PASS), 324
for biosimilar medicinal products, 401
postmarket clinical follow-up (PMCF)
Class III and implantable devices, 238–239, 260–261
for clinical efficacy evaluation, 298
manufacturer’s obligations for, 157
use in clinical strategy, 240
postmarket surveillance (PMS), 260
device technical documentation, 227
for generic medicinal products, 380
manufacturer, 117–118
postmarket surveillance requirements
combination products, 551
Potential Serious Risk for Public Health (PSRPH) application withdrawal in DCP, 345
preclinical testing
GLP regulations in, 301
OECD GLP principles, 303–304
See also Good Laboratory Practice; medical device preclinical testing
preclinical testing of devices
biocompatibility testing, 231, 234c, 235c
Design Traceability Matrix for, 231
electrical safety and magnetic disturbance testing, 233
nonclinical studies, 231, 235
packaging validation, 232
performance testing, 231
preclinical test plan
regulatory requirements, 230
standards requirements, 230
user requirements, 230
risk management requirements, 230
shelf life (aging) studies, 233
software verification and validation, 233
statistical methods, 234
sterilisation validation, 232–233
transport studies, 232
usability (human factors) studies, 233
predicate device
GSPRs requirements, 227
preliminary assessment report (PrAR)
Reference Member State (RMS) authoring of, 355–356
Prescription Medicines Code of Practice Authority (PMCPA), 111
pricing and reimbursement, 61–76
containment policies of Member States, 67
current trends, 67
economic evaluations, 66, 66f
fac tors affecting pricing for medicinal products,
61–62
food for special medical purposes (FSMPs), 516
legal framework, 62–63
link between models and HTA, 67–74
models and HTA case studies, 67–74
models for, 64
cost-based pricing, 63–64
reference-based, 63, 65t
value-based pricing, 64
pricing factors for, 62f
reference pricing system for generic products, 377–378
reimbursement, 65–67
vaccines, 498
primary mode of action (PMOA), combination products, 544–545
PRIME (PRIority MEdicines)
HTA/EMA collaboration for, 89
laws and regulations, 36–37
promotion. See advertising and promotion
Q
Qualified Person (QP/QPPV) generic medicinal products, 389
GMP certification, 331
for human tissues/ATMPs, 479t
pharmacovigilance (PV), 439
pharmacovigilance for medicinal products, 280
postmarket pharmaceutical compliance, 426–427
PSMF and, 387
in recall decisions, 119
signal management, 446
tissue establishment, 479
vaccine development, 490
vaccine release, 490
See also responsible person (RP)
Quality Assurance (QA) programme
GLP requirements, 305
Quality Management System (QMS) assessors and inspector relationship in, 364–365, 365f
for clinical evaluation procedures, 240
in clinical investigation and evaluations, 240
in clinical trial protocol, 330
for combination products, 550–551
in conformity assessment, 248
conformity assessment in, 136
EU IVDR requirements, 215
human tissue products regulation, 473
ICH QMS requirements, 365
pharmacovigilance factors for, 440
PMS requirements, 118
postmarket surveillance in, 117–118, 259
regulatory strategy for, 138
technical documentation for, 226
quality review of documents (QRD)
labelling templates, 407, 415
medicinal product authorisation procedures, 281, 351, 358
SmPC information requirements, 388, 448
templates in Centralised Procedure, 415
quality systems and inspectorate process
assessors and inspector relationship in, 365f
British Pharmacopoeia (BP), 373
EDQM inspection process, 369
Eurasian Economic Union, 374
European Pharmacopoeia (Ph. Eur.), 373
GCP inspections, 370–371
GDP inspections, 371
for generic medicinal products, 390
GLP inspections, 370
GMP inspections, 367–369
GMP/GDP Inspectors Working Group, 370
ICMRA, 374
industry associations, 374
for IVDs, 214–215
joint inspection program participants, 372–373
legal framework for, 366, 366f
list of other agency inspections, 371
MRAs for inspections, 371
OECD, 375
pharmaceutical regulation evolution, 363–364
pharmacopeial compendia, 373
PIC/S, 373
requirements for EU, 365
Swiss Pharmacopoeia (Ph. Helv.), 373
Quality-Adjusted Life Years (QUALYs)
in HTA assessment, 84
in pricing and reimbursement, 66

R
reference medicine, 377
pharmacopoeial compendia for API, 380
Reference Member State (RMS)
business validation and checklist for, 354
DCP role of, 355–356
Decentralised Procedure applications role and timeline, 287–288
decentralised procedure role, 344
follow-up referral, 292
initial product assessment, 342
MAA evaluation, 19
MAA presubmission meetings, 347
mutual recognition and decentralised procedure referrals, 293
Mutual Recognition Procedure (MRP), 345, 356–357
Mutual Recognition Procedure phase 2 timeline, 286
Mutual Recognition Procedure role, 286
PrAP from, 355
renewal date agreement with MAH, 424
selection for MAA, 285
selection of, 336
worksharing for MA maintenance, 359
reference-based pricing model, 63, 65t
referrals
community interest referral, 293
divergent decision referral, 293
European community referral, 292
follow-up referral, 292
generic medicinal product evaluation, 381
mutual recognition/decentralised procedure referral, 293
registration of medicinal products, 341–362
accelerated assessment, 347
adaptive pathway, 346
ASMF for, 350
bibliographic applications/well-established use, 349
of biosimilar medicinal products, 397–399
biosimilar medicinal products, 397–399
for biotechnology-derived product, 414–415
for biotechnology-derived products, 414–415
Certificate(s) of Suitability, 352
combination products, 544
conditional approval, 346
conditional authorisation, 346
content of submissions, 351, 351t
eCTD envelope and CTD format, 351–352
exceptional circumstances, 346–347
fixed combination, 349
full registration, 348
generic products, 391
genetic registration, 348
for human blood or plasma products, 523
hybrid registration, 348
informed consent, 349
MA maintenance, 359–360
MAA application types, 347–350
MAH liability and, 342
materials of human/animal origin, 352
mixed marketing, 350
orphan medicinal products, 342–343
other documentation, 358–359
paediatric investigations, 343–344
presubmission meeting request, 347
procedure types, 344–345
PSURs and PSUSAs, 360
questions on dossier, 358
referrals, 360
regulatory dossier changes/variations, 359
regulatory dossier submission, 352–353
regulatory dossier validation, 353–354
routes for, 523
scientific advice, 343
scientific advice application, 350–351
similar biological registration, 348–349
urgent safety restrictions, 360
Regulation defined, 184, 366
regulatory authorities
  Council of Europe, 365
  EMA, 1–5, 7–10
  European Commission (EC), 365
  European Medicines Agency (EMA), 365
  European Medicines Regulatory Network, 5–7
  Task Force for Relations with the United Kingdom (UKTF), 364, 366
regulatory dossier
  for blood/plasma products, 524–525
  Centralised Procedure, medicinal products, 354
  changes/variations for medicinal products, 359
  Decentralised Procedure (DCP), medicinal products, 355–356
  for IVD design, 215
  Mutual Recognition Procedure (MRP), medicinal products, 356–357
  National Procedure, medicinal products, 357
  submission for medicinal products, 352–353
  validation for medicinal products, 353–354
REgulatory FITness and performance programme (REFIT), 502, 506
regulatory information resources, 553–574
  agencies and committees, 557–561
  association electronic media, 569–570
  book publishers, 567–568
  commercial and government databases online, 565–567
  continued learning and associations, 570
  core SmPC guidance for vaccines, 496
  Council of Europe publications on blood/plasma products, 523–524
  device regulation, 555–556
  EDQM databases, 567t
  EMA committees and working parties, 558–559t
  EU and international organisations, 561–564
  EU laws and regulations, 556–557
  framework for medicinal products, human use, 554
  global regulatory coverage databases, 567–568
  industry resources in electronic newsletters, 569
  industry stakeholder organisation, 565t
  innovative medicines initiative (IMI), 564
medical product legislation in Eudralex, 554–555
national competent authorities listing, 562–563t
professional association/organisations, 564
regulators outside the EU, 565
regulatory system for medicines, 553–554
social networking and mobile apps, 571–572
regulatory strategy
  confirming strategy, 138–139
  developing and implementing, 136–138
  documentation of, 138–139
  information resources for development, 138
  key questions during development, 137t
  market considerations in, 135–136
  prescription to nonprescription strategy, 408
  review/update of, 139
reimbursement. See pricing and reimbursement
Reporting Member State
  clinical trial authorisation process, 311, 324–326
  low-intervention clinical trial determination, 329
reprocessing, 147
reproductive studies, 303
responsible person (RP)
  generic products, 386
  tissue quality systems, 478–479, 479t
See also Qualified Person (QP)
risk management plan (RMP), 425
  adaptive pathways and, 346
  for Advanced Therapy Medicinal Products (ATMPs), 466–467
  for ATMPs, 466–467
  biocompatibility testing, 230–231
  in device industry, 260
  generic medicinal products, 387
  pharmacovigilance modules, 444t
  preclinical device testing, 230
  requirements for, 440
See also ISO 14971; pharmacovigilance
S
Safeguard Clause
  action by Member States, 267
  action on conforming devices, 117
  comparison of health monitoring measures, 267–268, 267t
Safety (SAF) HTA model, 80
safety measures in clinical trials, 323
scientific advice and protocol assistance
  for MAA, 37–38
  review before EMA meeting, 48
Scientific Advice Working Party (SAWP), 37
Scientific Advisory Group (SAG) meeting, 55–56
scientific committees (EMA)
  MAA review, 53, 54t
scientific service implementation, 111
serious adverse events (SARs) for IMPs and NIMPs, 332
Single European Code (SEC), 476t, 485
dual-use plastics directive, 516
software
EU MDR and EU IVDR reclassification of, 142, 146, 167
GSPRs requirements, 222, 231
with medical devices, 26, 186, 200–201, 208, 545
preclinical device testing, 233
verification and validation of, 233, 234c
vigilance for, 261
somatic cell therapy medicinal products (sCTMPs)
clinical development, 465–466
intended use and manipulation criteria, 460–461
manufacturing process, 462
preclinical development, 463–464
Spain
competent authorities for pricing//reimbursement and HTA, 71
HTA in, 82t, 83t
National Health Service (SNS), 71
pricing/reimbursement procedures, 71–72
Spurious/Falsely-Labelled/Falsified/Counterfeit (SFFC) medicines, 121, 126, 129t, 132
Standard Assessment Review Timeline
EMA meeting preparation, MAA review, 55f
Standard Operating Procedures (SOPs), 306
Summary of Product Characteristics (SmPC)
advertising and promotion compliance, 104–107, 109
changes affecting safety, 360, 399–401, 424–425, 432 (see also pharmacovigilance)
generic and reference products, 33, 379, 382–383
human blood or plasma products, 522
as IMPD, 331
in MAA, 35
medicinal product MA maintenance, 279–280, 286–289, 292
national competent authority product authorisation, 320
product labelling, 388, 407, 427
QRD review, 358–359
for vaccines, 491, 492, 496
See also specific application procedures
Summary of Safety and Clinical Performance (SSCP), 238
Summary Technical Documentation (STED), 226–227
Supplementary Protection Certificate (SPC)
paediatric investigation incentives, 344
paediatric medicinal products, 94
protection of innovator medicine by, 379
supply chain controls: new MDR and IVDD regulation, 142–143
suspected unexpected serious adverse reactions (SUSARs)
electronic reporting, 318
reporting, 332–333
Swiss Pharmacopoeia (Ph. Helv.)
quality systems and inspectorate process, 373
T
technical documentation
of Essential Requirements compliance, 215
EU MDR and EU IVDR, 226–227
for IVDs, 215
“the garlic case”, 506
therapeutic interchangeability
biosimilar medicinal products, 22, 399
tissue-engineered products (TEPS)
clinical development, 466
decision tree for classification, 458f
intended use and manipulation criteria, 461
manufacturing process, 463
preclinical development, 465
toxicity studies
for biosimilar medicinal products, 395
preclinical device testing, 235c
preclinical testing, 302
traceability
new regulations, 143–144
SEC for tissues/ATMPs, 485
Traditional Herbal Medicinal Product Directive (THMPD), 409–410, 503, 506
traditional herbal medicinal products: regulation evolution, 23
Transmissible Spongiform Encephalopathy (TSE)
biotechnology-derived products, 417–418
blood and plasma evaluation for, 15, 524
Treaty on the Functioning of the EU, 62
trend reporting, 265
U
unique device identifiers (UDI), 138, 143, 215, 268, 485
United Kingdom (UK)
advertising and promotion, 111–112
assessors and inspector relationship in, 364–365
Brexit effects for quality management, 364–365
Brexit impact on medical devices, 272
competent authorities for pricing/reimbursement and HTA, 73
HTA in, 82t, 83t
implementation of ECTR in, 315
National Health Service (NHS), 73
pricing/reimbursement procedures, 73–74
United States (US): GLP regulations in, 302
Urgent Safety Restriction (USR)
biosimilar medicinal products, 400
dossier requirements for, 426
timeframe for implementation, 432–433
variation classification and, 436
usability testing, 234c

V
vaccine adverse event reporting system (VAERS), 493
Vaccine Antigen Master File (VAMF)
development processes for, 491, 492
EU regulations, 21
veterinary vaccines, 23
vaccines, 489–500
adjuvants in, 496–497
classification and development pathway, 489–490
clinical studies, 492
CTA for, 490–491
DNA and therapeutic vaccines/GMO-based, 497–498
GMO-based vaccines, 497–498
guidance on, 496
immunomodulators in, 497
licensure, 492–498
lot release, 492
manufacturing process, 490–491
nonclinical studies, 491–492
overview, 498
pandemic influenza, 496
pharmacovigilance (PV), 493
prepandemic influenza vaccines, 496
pricing and reimbursement, 498
seasonal influenza vaccines, 494–495, 495f
for special populations, 494
vaccines, 492–493
VAMF, 491
VAMF certification, 491t
VAMF certification and requirements, 21
vector use in, 497
value-based pricing model, 64
veterinary medicinal products
CMDv, 18
CVMP role in authorisation, 8
GMP inspections for, 373–374
national competent authorities for, 6–7
OMCLs testing, 522

pharmaceutical regulation evolution, 22–23
regulatory agencies for, 2–3, 4–5, 365–366
regulatory principles, 22–23
scientific advice and protocol assistance, 48
variations to MAAs, 20–21
See also specific application procedures
vigilance procedures for IVDs, 214–215
viral clearance, 418
Voluntary Harmonisation Procedure (VHP)
CTFG and, 336
implementation and guidance for, 313

W
worksharing in market authorisation maintenance, 359
World Health Organization (WHO)
falsified medicine initiative/IMPACT, 122, 564
generic medicinal product definition, 377
Global Surveillance and Monitoring System (GSMS), 130
HTA definition by, 66
International Clinical Trials Registry Platform (WHO ICTRP), 335
paediatric medicine initiative, 100
pandemic vaccine development and, 496
wrongly affixed CE-marking, 117